At the news
? NEUTRALIMPACT 5/10 8-K filed Nov 12, 2026 at 16:07 ET
SELLAS reported Q3 2026 net loss of $10.1M ($0.05 per share), in line with the $-0.05 consensus. Cash and equivalents stood at $134.7M. The key catalyst is the upcoming topline readout of the Phase 3 REGAL trial of GPS in AML, expected this month, and preliminary Phase 2 SLS009 data expected in Q4 2026.
- Q3 2026 net loss of $10.1M, or $0.05 per share, vs $6.8M loss ($0.06) in Q3 2025
- Cash and cash equivalents of $134.7M as of September 30, 2026
- 80th event in Phase 3 REGAL trial of GPS occurred in October 2026; topline results expected this month
- 40 of 80 patients enrolled in Phase 2 trial of SLS009 in newly diagnosed AML; preliminary topline data expected Q4 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access